AngloGold Ashanti to Join Russell 3000 and Other Russell Equity Indexes on 27 June 2025
Final index membership will become effective after the U.S. market closes on Friday, 27 June 2025, with rebalanced index constituents reflected in trading beginning Monday, 30 June 2025.
"This is an important milestone for AngloGold Ashanti," said Alberto Calderon, Chief Executive Officer of AngloGold Ashanti. "Our inclusion in this important family of US equity market indexes will help further increase liquidity and unlock long-term value for our shareholders."
Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to data as of the end of June 2024, about $10.6 trillion in assets are benchmarked against the Russell U.S. Indexes, which belong to FTSE Russell, the global index provider. The reconstitution of the Russell U.S. Indexes ranks the 4,000 largest U.S. stocks by market capitalisation to reflect changes in the investable equity market. This year's rebalance is expected to drive more than $53 billion in passive flows, and marks one of the highest-volume trading days of the year.
AngloGold Ashanti's anticipated inclusion in these benchmark equity indexes on 27 June 2025 follows the move of the Company's primary listing to the NYSE in September 2023.
About AngloGold Ashanti
AngloGold Ashanti plc is an independent, global gold mining company with a diversified portfolio of operations, projects, and exploration activities across ten countries. Headquartered in Denver, Colorado, the Company is committed to operational excellence, disciplined capital allocation, and sustainable value creation. AngloGold Ashanti has its primary listing on the NYSE and secondary listings on the Johannesburg Stock Exchange (A2X and JSE) and the Ghana Stock Exchange (GSE).
For more information, visit: www.anglogoldashanti.com
About FTSE Russell
FTSE Russell is a leading global index provider, benchmarking approximately $18.1 trillion in assets. The Russell U.S. Indexes are designed to represent the U.S. equity market with transparent, rules-based methodologies. Beginning in 2026, FTSE Russell will transition to semi-annual reconstitutions to reflect evolving market conditions.
For more information on the 2025 reconstitution, visit: https://www.lseg.com/en/ftse-russell/russell-reconstitution#overview
JSE Sponsor: The Standard Bank of South Africa
Forward-looking statements
Certain statements contained in this document, other than statements of historical fact, including, without limitation, those concerning the economic outlook for the gold mining industry, expectations regarding gold prices, production, total cash costs, all-in sustaining costs, all-in costs, cost savings and other operating results, return on equity, productivity improvements, growth prospects and outlook of AngloGold Ashanti's operations, individually or in the aggregate, including the achievement of project milestones, commencement and completion of commercial operations of certain of AngloGold Ashanti's exploration and production projects and the completion of acquisitions, dispositions or joint venture transactions, AngloGold Ashanti's liquidity and capital resources and capital expenditures, the consequences of the COVID-19 pandemic and the outcome and consequences of any potential or pending litigation or regulatory proceedings or environmental, health and safety issues, are forward-looking statements regarding AngloGold Ashanti's financial reports, operations, economic performance and financial condition. These forward-looking statements or forecasts are not based on historical facts, but rather reflect our current beliefs and expectations concerning future events and generally may be identified by the use of forward-looking words, phrases and expressions such as "believe", "expect", "aim", "anticipate", "intend", "foresee", "forecast", "predict", "project", "estimate", "likely", "may", "might", "could", "should", "would", "seek", "plan", "scheduled", "possible", "continue", "potential", "outlook", "target" or other similar words, phrases, and expressions; provided that the absence thereof does not mean that a statement is not forward-looking. Similarly, statements that describe our objectives, plans or goals are or may be forward-looking statements. These forward-looking statements or forecasts involve known and unknown risks, uncertainties and other factors that may cause AngloGold Ashanti's actual results, performance, actions or achievements to differ materially from the anticipated results, performance, actions or achievements expressed or implied in these forward-looking statements. Although AngloGold Ashanti believes that the expectations reflected in such forward-looking statements and forecasts are reasonable, no assurance can be given that such expectations will prove to have been correct. Accordingly, results, performance, actions or achievements could differ materially from those set out in the forward-looking statements as a result of, among other factors, changes in economic, social, political and market conditions, including related to inflation or international conflicts, the success of business and operating initiatives, changes in the regulatory environment and other government actions, including environmental approvals, fluctuations in gold prices and exchange rates, the outcome of pending or future litigation proceedings, any supply chain disruptions, any public health crises, pandemics or epidemics (including the COVID-19 pandemic), the failure to maintain effective internal control over financial reporting or effective disclosure controls and procedures, the inability to remediate one or more material weaknesses, or the discovery of additional material weaknesses, in the Company's internal control over financial reporting, and other business and operational risks and challenges and other factors, including mining accidents. For a discussion of such risk factors, refer to AngloGold Ashanti's annual report on Form 20-F for the financial year ended 31 December 2024 filed with the United States Securities and Exchange Commission (SEC). These factors are not necessarily all of the important factors that could cause AngloGold Ashanti's actual results, performance, actions or achievements to differ materially from those expressed in any forward-looking statements. Other unknown or unpredictable factors could also have material adverse effects on AngloGold Ashanti's future results, performance, actions or achievements. Consequently, readers are cautioned not to place undue reliance on forward-looking statements. AngloGold Ashanti undertakes no obligation to update publicly or release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except to the extent required by applicable law. All subsequent written or oral forward-looking statements attributable to AngloGold Ashanti or any person acting on its behalf are qualified by the cautionary statements herein.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250611694187/en/
Contacts
Media Andrea Maxey+61 08 9425 4603 / +61 400 072 199amaxey@aga.gold
General inquiriesmedia@anglogoldashanti.com
Investors Andrea Maxey+61 08 9425 4603 / +61 400 072 199amaxey@aga.gold
Yatish Chowthee+27 11 637 6273 / +27 78 364 2080yrchowthee@aga.gold
Website: www.anglogoldashanti.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
CPI in July Puts Pre-Markets in a Good Mood
Tuesday, August 12, 2025Pre-market futures are rising from modest levels in the green this morning, a direct result of seeing better-than-expected Consumer Price Index (CPI) numbers in the July report ahead of the opening bell. Just prior to this important economic release — including an updated Inflation Rate — we were +44 points on the Dow, +7 on the S&P 500 and +38 on the Nasdaq, currently we are +275 points on the Dow, +43 points on the S&P 500 and +190 points on the small-cap Russell 2000 is up +1.24%, or +27 points on the news, the biggest jump of all the major indexes this morning. We're also seeing bond yields tick up on the news, by nearly 30 basis points (bps) on the 10-year to 4.27% — now back up over the median level of the past year, after spending the month of August below it so far — and +10 bps to 3.73%. Part of this relief rally may also be due to yet another reprieve on Chinese tariffs from over the weekend, kicked out another 90 days to November 10th. Recall that post-'Liberations Day,' China was suffering the wrath of President Trump and was looking at +145% tariffs on imported Chinese goods, which for many American companies make up more than 50% on its inventory. But this was initially pushed out to July 9th, then August 1st, then August 12th (today), now November this morning's good news — aligned with an overall better-than-expected Q2 earnings season now on the 'back nine' — is multi-factorial: tariff inflation has yet to hit the economy in the mouth (and according to some, maybe never will) and tariff policy continues to push out further down the calendar. Not a bad set-up for a nice day for the stock market. CPI for July Mostly In-Line Headline month-over-month Consumer Price Index (CPI) for the month of July came in at +0.2%, in-line with expectations and 10 bps lower than June's +0.3%. Core CPI month over month — subtracting volatile food and energy prices — was also in-line with estimates at +0.3%, +10 bps from the previous over year CPI on headline, aka the 'Inflation Rate,' was lower by 10 bps from expectations to +2.7%, in-line month over month. This figure remains in the pocket between recent lows (+2.3% in April) and +3.0% in January. Core CPI year over year was the highest print of this series, +3.1%, the largest number since February and +20 bps higher month over a positive attitude from market participants on inflation this morning. We're not seeing tariffs appear in things like apparel at this point, energy prices have remained lower, and owner's equivalent rent have kept steady. Furnishings and Services, meanwhile, have begun to show some signs of inflation. Q2 Earnings Before the Bell: ONON, SFD, TME On Semiconductor ONON shares are up +14% in early trading on +32% net sales growth year over year, led by +47.2% in Direct-to-Consumer (DTC), +47.2%, and Adjusted EBITDA +220 bps to +18.2%. But the bottom line provided a big -145.8% earnings miss to -$0.11 per share. Meanwhile, Smithfield Foods SFD missed earnings estimates by a penny to 55 cents per share, helping send the stock down -3% so far this morning, even as the company's operating profit outlook improved. Tencent Music Entertainment TME beat estimates by +15% this morning, and shares are up +7% on the or comments about this article and/or author? Click here>> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Smithfield Foods, Inc. (SFD) : Free Stock Analysis Report Tencent Music Entertainment Group Sponsored ADR (TME) : Free Stock Analysis Report On Holding AG (ONON) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
2 hours ago
- Business Wire
Industry Leader in Lyophilization, Dr. Serguei Tchessalov, Partners with BioTechnique ® to Enhance Customer Capabilities
YORK, Pa.--(BUSINESS WIRE)--BioTechnique ® LLC ('BioTechnique' or the 'Company') proudly welcomes Dr. Serguei Tchessalov, a globally recognized subject matter expert in lyophilization, whose decades of experience in formulation development, process design, and scale-up bring invaluable insight to clients navigating complex biologic and vaccine manufacturing. With over 40 years of experience spanning both Russia and the United States, Dr. Tchessalov brings deep expertise in the formulation and freeze-drying of bacterial, viral, and mRNA-based vaccines, proteins, and other complex biologics. He holds a Ph.D. in Biotechnology Engineering from the Institute of Applied Biochemistry in Moscow, where his research focused on novel formulation and process control methods for lyophilization. After completing postdoctoral training with Professor Michael Pikal at the University of Connecticut, he went on to hold roles at Immunex, Wyeth, and Pfizer, contributing to industry-leading development efforts. Dr. Tchessalov is the founder of SN Lyophilization, a consulting firm dedicated to freeze-drying and parenteral drug product processing. With over 30 scientific publications to his name, his current work focuses on lyophilization scale-up and transfer, as well as processing operations including filtration, filling, freezing, and thawing. His partnership with BioTechnique strengthens the company's ability to support clients with practical, science-driven solutions across the entire drug product lifecycle. BioTechnique ® 's Lyophilization Capabilities At BioTechnique ®, lyophilization is a core competency backed by robust infrastructure and scientific expertise. Our state-of-the-art, aseptic manufacturing facility is equipped to support both clinical and commercial-scale freeze-drying of biologics, including monoclonal antibodies, peptides, vaccines, and other sensitive drug products. We offer flexible lyophilizer configurations, precise cycle development, and seamless tech transfer—all executed under strict cGMP conditions. Whether clients require formulation support, cycle optimization, troubleshooting, or full-process development, BioTechnique provides tailored solutions that prioritize product stability, yield, and regulatory compliance. With Dr. Tchessalov's guidance, our clients gain not only access to advanced modeling tools and industry best practices, but also the strategic insight needed to successfully navigate the complexities of lyophilization from early development through commercialization. For more information on BioTechnique's capabilities, visit
Business Wire
3 hours ago
- Business Wire
TriSalus Life Sciences Reports Second Quarter 2025 Results and Reiterates 2025 Guidance
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the 'Company'), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announces financial results for the quarter ended June 30, 2025, and provides an operational update. 'TriSalus continued to deliver strong commercial momentum in the second quarter, underscoring the growing clinical adoption of our TriNav ® product suite and proprietary PEDD ® platform across a broad range of solid tumor indications,' said Mary Szela, President and CEO of TriSalus. 'We are pleased to reaffirm our full-year revenue growth guidance of 50%, reflecting increasing market penetration within liver-directed therapies. We will continue to invest in clinical data to extend the benefits of our PEDD technology platform to new embolization applications. With a strategic shift toward partnering development of Nelitolimod and an expanded focus on liver-directed therapies and new applications, we are energized by the opportunity to bring our PEDD technology to a wider range of patients which will not only support improved clinical outcomes but also drive deeper physician engagement and commercial momentum, fueling our long-term vision.' Second Quarter 2025 Highlights Generated $11.2 million in net sales, a 52% increase year-over-year, and sequential growth of 22% over the first quarter 2025. Continued strong commercial momentum with expanded use of TriNav ® in liver embolization and continued to further develop new applications in new clinical settings focused on the interventional radiology specialty. Expanded product portfolio with the successful launch of TriNav ® FLX, the latest advancement in Pressure-Enabled Drug Delivery (PEDD). Designed with a more flexible distal tip, TriNav FLX enhances navigability through tortuous vessels—providing an effective solution for physicians previously limited by anatomical barriers to PEDD adoption. Early market response has been strong, with sales surpassing internal projections. Subsequent to the second quarter, the Company simplified its capital structure through the successful completion of an exchange offering of previously issued Series A Preferred stock. Second Quarter 2025 Financial Highlights Revenue, all from the sale of the TriNav system, was $11.2 million for the three months ended June 30, 2025, an increase of 52% compared to the same period in 2024 and 22% sequential growth. Revenue growth was driven primarily by increased selling resources and increased market share. Gross margins were 84% in the second quarter, compared to 88% in the same period of 2024. The year-over-year decline was primarily driven by lower manufacturing efficiency associated with newly launched products, a dynamic we expect to improve as production scales and processes mature over the course of the year. Research and Development (R&D) expenses were approximately $3.9 million, compared to $4.7 million for the same quarter of the prior year. The decline in R&D costs is primarily a result of a decline in clinical trial costs relating to Nelitolimod. Sales and Marketing (S&M) expenses were approximately $7.2 million in the second quarter, compared to $6.0 million for the same quarter of the prior year. The year-over-year increase reflects continued investment in the expansion of our commercial organization. General & Administrative (G&A) expenses were approximately $5.7 million, compared to $4.0 million for the same quarter of the prior year. G&A costs include non-cash stock-based compensation of $1.2 million and $0.7 million, respectively, for the same periods. The increase in G&A costs is primarily a result of professional services related to legal services and audit. Operating losses were $7.3 million, compared to Operating losses of $8.2 million for the same period in 2024. Current reductions in operating losses are due to reduced research and development expenses associated with the ramp-down of Nelitolimod clinical trial spending. Net loss attributable to common stockholders was $9.0 million, compared to $5.1 million for the same period in 2024, primarily due to non-cash adjustments to the fair value of our contingent earnout liability. The basic and diluted loss per share was $0.27, compared to $0.21 for the same period in 2024. As of June 30, 2025, cash and cash equivalents totaled $26.5 million providing sufficient runway to reach positive adjusted EBITDA in the first half of 2026. The non-GAAP measure of adjusted EBITDA is reconciled in the table below as the Company believes it is an important measure of performance. Adjusted EBITDA losses were $5.3 million, compared to losses of $6.7 million for the same period in 2024. Currently, reductions in adjusted EBITDA losses are due to increased sales, reduced research and development expenses and increased stock compensation in 2025. Conference Call The Company will host a conference call and webcast today at 4:30 PM eastern time to discuss its financial results for the quarter ended June 30, 2025. Parties interested in participating by phone should register using this online form. After registering for the webcast, dial-in details will be provided in an auto-generated e-mail containing a link to the conference phone number along with a personal pin. The event will also be webcast live on the investor relations section of TriSalus' website. A replay will also be available on the website following the event. About TriSalus Life Sciences TriSalus Life Sciences ® is an oncology focused medical technology company seeking to transform outcomes for patients with solid tumors by integrating its innovative delivery technology with standard-of-care therapies, and with its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of different therapeutic and technology applications. The Company's platform includes devices that utilize a proprietary drug delivery technology and a clinical stage investigational immunotherapy. The Company's two FDA-cleared devices use its proprietary Pressure-Enabled Drug Delivery™ (PEDD) approach to deliver a range of therapeutics: the TriNav ® Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. The PEDD technology is a novel delivery approach designed to address the anatomic limitations of arterial infusion for the pancreas. The PEDD approach modulates pressure and flow in a manner that delivers more therapeutic to the tumor and is designed to reduce undesired delivery to normal tissue, bringing the potential to improve patient outcomes. Nelitolimod, the Company's investigational immunotherapeutic candidate, is designed to improve patient outcomes by treating the immunosuppressive environment created by many tumors and which can make current immunotherapies ineffective in the liver and pancreas. Patient data generated during Pressure-Enabled Regional Immuno-Oncology™ (PERIO) clinical trials support the hypothesis that nelitolimod delivered via the PEDD technology may have favorable immune effects within the liver and systemically. The target for nelitolimod, TLR9, is expressed across cancer types and the mechanical barriers addressed by the PEDD technology are commonly present as well. The Company is in the final stages of data completion for a number of phase 1 clinical trials and will begin exploring partnership opportunities for development. Forward Looking Statements Statements made in this press release regarding matters that are not historical facts are 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the benefits and potential benefits of the Company's PEDD drug delivery technology, TriNav ® system and nelitolimod investigational immunotherapy, and the Company's ability to execute on its strategy. Risks that could cause actual results to differ from those expressed in these forward-looking statements include risks associated with clinical development and regulatory approval of drug delivery and pharmaceutical product candidates, including that future clinical results may not be consistent with patient data generated during the Company's clinical trials, the cost and timing of all development activities and clinical trials, unexpected safety and efficacy data observed during clinical studies, the risks associated with the credit facility, including the Company's ability to remain in compliance with all its obligations thereunder to avoid an event of default, the risk that the Company will continue to raise capital through the issuance and sale of its equity securities to fund its operations, the risk that the Company will not be able to achieve the applicable revenue requirements to access additional financing under the credit facility, the risk that the Company will not become profitable on its expected timeline, if at all, the risk that the reported financial results will differ from the estimates provided in this press release, changes in expected or existing competition or market conditions, changes in the regulatory environment, unexpected litigation or other disputes, unexpected expensed costs, made in this press release regarding matters that are not historical facts are 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the benefits and potential benefits of the Company's PEDD drug delivery technology, TriNav ® system and nelitolimod investigational immunotherapy, and the Company's ability to execute on its strategy. Risks that could cause actual results to differ from those expressed in these forward-looking statements include risks associated with clinical development and regulatory approval of drug delivery and pharmaceutical product candidates, including that future clinical results may not be consistent with patient data generated during the Company's clinical trials, the cost and timing of all development activities and clinical trials, unexpected safety and efficacy data observed during clinical studies, the risks associated with the credit facility, including the Company's ability to remain in compliance with all its obligations thereunder to avoid an event of default, the risk that the Company will continue to raise capital through the issuance and sale of its equity securities to fund its operations, the risk that the Company will not be able to achieve the applicable revenue requirements to access additional financing under the credit facility, the risk that the Company will not become profitable on its expected timeline, if at all, the risk that the reported financial results will differ from the estimates provided in this press release, changes in expected or existing competition or market conditions, changes in the regulatory environment, unexpected litigation or other disputes, unexpected expensed costs, and other risks described in the Company's filings with the Securities and Exchange Commission under the heading 'Risk Factors.' All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made except as required by law. TRISALUS LIFE SCIENCES, INC. Condensed Consolidated Balance Sheets (unaudited, in thousands) December 31, 2024 Assets Current assets: Cash and cash equivalents $ 26,490 $ 8,525 Accounts receivable, net 5,571 5,087 Inventory, net 3,807 4,048 Prepaid expenses 2,216 3,009 Total current assets 38,084 20,669 Property and equipment, net 1,711 1,669 Right-of-use assets 1,103 1,210 Other assets 419 423 Total assets $ 41,317 $ 23,971 Liabilities and Stockholders' Deficit Current liabilities: Trade payables $ 1,902 $ 2,274 Accrued liabilities 7,078 7,355 Short-term lease liabilities 123 216 Other current liabilities 221 383 Total current liabilities 9,324 10,228 Long-term debt, net of unamortized discount and debt issuance costs 32,274 22,084 Revenue base redemption liability 358 507 Long-term lease liabilities 1,265 1,329 Contingent earnout liability 7,522 7,401 Warrant and SEPA liabilities 9,997 8,316 Total liabilities 60,740 49,865 Commitments and contingencies Stockholders' deficit: Preferred Stock, Convertible Series A, $0.0001 par value per share, $10.00 liquidation value per share. Authorized 10,000,000 shares at June 30, 2025 and December 31, 2024, respectively; issued and outstanding, 3,594,002 and 3,985,002 shares at June 30, 2025, and December 31, 2024, respectively. — — Common stock, $0.0001 par value per share. Authorized 400,000,000 shares at June 30, 2025 and December 31, 2024, respectively; issued and outstanding, 37,983,259 and 31,279,264 shares at June 30, 2025, and December 31, 2024, respectively. 3 3 Additional paid-in capital 278,786 253,652 Accumulated deficit (298,212 ) (279,549 ) Total stockholders' deficit (19,423 ) (25,894 ) Total liabilities and stockholders' deficit $ 41,317 $ 23,971 Expand Non-GAAP Financial Measure To supplement the financial results presented in accordance with GAAP, TriSalus has also included in this press release non-GAAP adjusted EBITDA, which excludes from net loss, income tax expense, interest expense, interest income, change in fair value of SEPA, warrant and revenue-base redemption liabilities, change in fair value of contingent earn out liability, stock-based compensation expense and depreciation. These non-GAAP financial measures are not prepared in accordance with GAAP, do not serve as an alternative to GAAP and may be calculated differently than similar non-GAAP financial information disclosed by other companies. TriSalus encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP financial information and the reconciliation between these presentations set forth below, to more fully understand TriSalus' business. TriSalus believes that the presentation of these non-GAAP financial measures provides useful supplemental information to, and facilitates additional analysis by, investors. In particular, TriSalus believes that these non-GAAP financial measures, when considered together with its financial information prepared in accordance with GAAP, can enhance investors' and analysts' ability to meaningfully compare TriSalus' results from period to period, and to identify operating trends in TriSalus' business.
